Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: ticagrelor

« Back to Dashboard
Ticagrelor is the generic ingredient in one branded drug marketed by Astrazeneca Lp and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has two hundred and eight patent family members in forty-three countries.

There are seventeen drug master file entries for ticagrelor. Three suppliers are listed for this compound.

Summary for Generic Name: ticagrelor

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Drug Master File Entries: see list17
Suppliers / Packaging: see list7

Clinical Trials for: ticagrelor

High Ticagrelor Loading Dose in STEMI
Status: Completed Condition: Coronary Artery Disease

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Status: Completed Condition: Coronary Artery Disease

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
Status: Recruiting Condition: End Stage Renal Disease; Vascular Access Patency

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Status: Recruiting Condition: Coronary Artery Disease; Acute Coronary Syndrome

Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome
Status: Not yet recruiting Condition: Acute Coronary Syndrome

OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)
Status: Completed Condition: ST Elevation Myocardial Infarction

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Status: Recruiting Condition: Coronary Artery Disease

Cangrelor Ticagrelor Transition Study
Status: Completed Condition: Coronary Artery Disease

Ticagrelor Pharmacokinetics in NSTEMI
Status: Recruiting Condition: Myocardial Infarction

Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI
Status: Recruiting Condition: Myocardial Ischemia; Coronary Artery Disease; Endothelial Dysfunction

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYes<disabled><disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYes6,525,060<disabled>YY<disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYes7,265,124<disabled>YY<disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYes8,425,934<disabled>Y<disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYes6,251,910<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ticagrelor

Country Document Number Publication Date
European Patent Office2322513May 18, 2011
Slovakia16852002Aug 05, 2003
Slovakia287817Nov 04, 2011
World Intellectual Property Organization (WIPO)2008024045Feb 28, 2008
Argentina062451Nov 12, 2008
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc